IDXX · Analysis updated Nov 2, 2026, 10:36 AM ET

Why is IDEXX Laboratories, Inc. (IDXX) stock moving?

IDEXX sells tests and lab services that vets use on cats and dogs. Third-quarter sales grew 10% to $1.21B and earnings per share rose 18%. It raised its full-year sales and profit outlook, and the stock jumped about 16% to around $641.

News behind the analysis

IDEXX Labs beats estimates, raises guidance as stock gains
Investing.com (via Yahoo Finance) · Nov 1, 2026
EPS $3.96 vs $3.72; revenue $1.21B (+10%); full-year revenue and EPS guidance raised above consensus.
IDEXX Laboratories Announces Third Quarter Results
IDEXX Laboratories (Business Wire) · Nov 1, 2026
Company release: 1,900+ inVue Dx placements; installed base near 11,000; EPS guide raised $0.25 at the midpoint.
IDEXX (NASDAQ: IDXX) EPS jumps 18% and guidance rises, but the margin outlook slips
Daily Political · Nov 1, 2026
Details the one-off EPS items and the 20-basis-point cut to the operating-margin outlook.
IDEXX Laboratories (NASDAQ:IDXX) Q3 EPS Beat and Raised Guidance Fuel Relief Rally Despite In-Line Revenue
ChartMill · Nov 1, 2026
Frames revenue as in line and the guide midpoint as slightly below some estimates; CoVet AI acquisition.
Earnings call transcript: IDEXX beats Q3 2026 estimates and raises outlook
Investing.com · Nov 1, 2026
Management says it keeps outgrowing a difficult market for vet visits; stock up about 17% before the open.

In the Daily Standout

November 2, 2026: the Daily Standout +16.33%

For informational and educational purposes only. Not investment advice. Prices are an intraday snapshot and move quickly; sentiment and confidence scores are model opinions, not guarantees. Do your own research.